Ran Jin

Amgen (United States) — United States

Medicine · Health Sciences

16h-index1.3kcitations57works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(19), Biosimilars and Bioanalytical Methods(17), Diet, Metabolism, and Disease(13), Liver Disease and Transplantation(7), Diet and metabolism studies(6)

Publications57 total

Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Circulation Population Health and Outcomes·2026
Abstract 4363106: Real-World Effectiveness of Evolocumab in Reducing Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Circulation·2025
Abstract 4354732: Longitudinal LDL-C Control Among Patients With ASCVD and Elevated Baseline LDL-C: Insights From the cvMOBIUS-2 Registry
Circulation·2025
EVALUATING THE IMPACT OF LDL-C REDUCTION ON RECURRENT MI AND STROKE RELATED HOSPITALIZATIONS USING CAUSAL MACHINE LEARNING IN A REAL WORLD DATA
Journal of the American College of Cardiology·2025Open Access
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
Rheumatology and Therapy·2025Open Access
Abstract 4138757: Lipid-Lowering Therapy Intensification and Low-Density Lipoprotein Cholesterol Testing Following a Major Cardiovascular Event or Procedure in Adult Patients in the United States
Circulation·2024
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
Rheumatology and Therapy·2024Open Access
Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease
Therapeutic Advances in Gastroenterology·2024· 2 citedOpen Access
Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe
Advances in Therapy·2023· 10 citedOpen Access
43187 Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 (AMGEVITA®) in Patients with Psoriasis: An Observational Study Using German and French Pharmacy Claims Databases
Journal of the American Academy of Dermatology·2023Open Access
42268 Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe
Journal of the American Academy of Dermatology·2023Open Access
Tu1785 TREATMENT PATTERNS OF AN INFLIXIMAB BIOSIMILAR (ABP 710) AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A RETROSPECTIVE US CLAIMS DATABASE ANALYSIS
Gastroenterology·2023
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
Therapeutic Advances in Medical Oncology·2023· 9 citedOpen Access
2,3,5,4-Tetrahydroxystilbene-2-O-Β-D-Glucoside Inhibiting Hepatocytes Injury Through Reducing the Expression of Tumor Necrosis Factor-a in LPSStimulated Kupffer Cells via Regulating PPAR-γ/NFκB
Austin Journal of Pharmacology and Therapeutics·2022Open Access
S1041 Treatment Patterns of an Adalimumab Biosimilar (ABP 501) Among Patients With Inflammatory Bowel Disease: An Observational Study Using German Pharmacy Claims Database
The American Journal of Gastroenterology·2022
Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb.
Journal of Clinical Oncology·2022· 1 cited
REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE
Inflammatory Bowel Diseases·2022· 1 citedOpen Access
REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE
Gastroenterology·2022· 1 citedOpen Access
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer
Future Oncology·2021· 15 citedOpen Access
Disparities in Risks of Inadequate and Excessive Intake of Micronutrients during Pregnancy
Journal of Nutrition·2021· 42 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Miriam B. Vos(22), Ngoc‐Anh Le(12), Juna V. Konomi(8), Jean A. Welsh(7), Neil A. Accortt(7), Darcie Sandschafer(6), Dean P. Jones(5), James D. Otvos(5), James Piercy(5), Waldemar Radziszewski(5), Jeffrey R. Holzberg(4), Craig J. McClain(4), Jennifer K. Frediani(4), Rebecca Cleeton(4), Joanne E. Tomassini(4), Andrew M. Tershakovec(4), David Neff(4), Peter W.F. Wilson(4), Delphine Courmier(4), Rachael Meadows(4)